22q11.2 Deletion Syndrome Market Trends by 2034, Point to Steady Growth Ahead, DelveInsight Analysis Reveals

DelveInsight's "22q11.2 Deletion Syndrome Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the 22q11.2 Deletion Syndrome, historical and forecasted epidemiology as well as the 22q11.2 Deletion Syndrome market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

To Know in detail about the 22q11.2 Deletion Syndrome market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; 22q11.2 Deletion Syndrome Market Forecast
https://www.delveinsight.com/sample-request/22q112-deletion-syndrome-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Some of the key facts of the 22q11.2 Deletion Syndrome Market Report:
• The 22q11.2 Deletion Syndrome market size is anticipated to grow with a significant CAGR during the study period (2020-2034)
• In April 2025, ZYN002 is the first pharmaceutically produced synthetic cannbidiol formulated as a patented permeation-enhanced gel for transdermal absorption directly through the skin into the bloodstream-completely. Unlike cannabis-derived products, ZYN002 is synthetically manufactured in a cGMP-certified facility and does not cause the psychoactive effects associated, If approved, it may qualify as a nonscheduled medication. The active compound, cannbidiol, has been granted Orphan Drug Designation by both the U.S. FDA and the European Medicines Agency (EMA) for Fragile X Syndrome (FXS) and 22q11.2 deletion syndrome (22q). Moreover, ZYN002 has also received FDA Fast Track designation for addressing behavioral symptoms in FXS.
• In October 2024, HARMONY BIOSCIENCES, ZYN-002, expects to begin a pivotal Phase 3 trial for 22q11.2 deletion syndrome (22q) in 2025.
• In 2023, the United States reported the highest number of total prevalent cases of 22q11.2 deletion syndrome across the 7MM.
• In 2023, the EU4 and the UK accounted for approximately 40% of the total prevalent cases of 22q11.2 deletion syndrome in the 7MM.
• In 2023, the majority of 22q11.2 deletion syndrome cases were diagnosed in the 6-12 year age group across the 7MM.
• In 2023, the majority of 22q11.2 deletion syndrome cases were diagnosed in individuals aged 6-12 years across the 7MM.
• Key 22q11.2 Deletion Syndrome Companies: Zynerba Pharmaceuticals, Inc., Nobias Therapeutics, Inc., Bausch Health Americas, Inc., and others
• Key 22q11.2 Deletion Syndrome Therapies: ZYN002, NB-001, Metyrosine, and others
• The 22q11.2 Deletion Syndrome market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage 22q11.2 Deletion Syndrome pipeline products will significantly revolutionize the 22q11.2 Deletion Syndrome market dynamics.

22q11.2 Deletion Syndrome Overview
22q11.2 Deletion Syndrome, also known as DiGeorge Syndrome or Velocardiofacial Syndrome, is a genetic disorder caused by the deletion of a small segment of chromosome 22. It can lead to a wide range of symptoms, including heart defects, immune system problems, developmental delays, speech and language difficulties, and learning challenges. Individuals with this syndrome may also have distinct facial features and may be at a higher risk for psychiatric conditions. The severity and range of symptoms can vary greatly, and treatment focuses on addressing specific health concerns and providing supportive care.

Get a Free sample for the 22q11.2 Deletion Syndrome Market Report:
https://www.delveinsight.com/report-store/22q112-deletion-syndrome-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

22q11.2 Deletion Syndrome Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

22q11.2 Deletion Syndrome Epidemiology Segmentation:
The 22q11.2 Deletion Syndrome market report proffers epidemiological analysis for the study period 2020-2034 in the 7MM segmented into:
• Total Prevalence of 22q11.2 Deletion Syndrome
• Prevalent Cases of 22q11.2 Deletion Syndrome by severity
• Gender-specific Prevalence of 22q11.2 Deletion Syndrome
• Diagnosed Cases of Episodic and Chronic 22q11.2 Deletion Syndrome

Download the report to understand which factors are driving 22q11.2 Deletion Syndrome epidemiology trends @ 22q11.2 Deletion Syndrome Epidemiology Forecast
https://www.delveinsight.com/sample-request/22q112-deletion-syndrome-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

22q11.2 Deletion Syndrome Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the 22q11.2 Deletion Syndrome market or expected to get launched during the study period. The analysis covers 22q11.2 Deletion Syndrome market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the 22q11.2 Deletion Syndrome Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

22q11.2 Deletion Syndrome Therapies and Key Companies
• ZYN002: Zynerba Pharmaceuticals, Inc.
• NB-001: Nobias Therapeutics, Inc.
• Metyrosine: Bausch Health Americas, Inc.

Discover more about therapies set to grab major 22q11.2 Deletion Syndrome market share @ 22q11.2 Deletion Syndrome Treatment Market
https://www.delveinsight.com/sample-request/22q112-deletion-syndrome-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

22q11.2 Deletion Syndrome Market Strengths
• 22q11.2 deletion syndrome is a rare genetic condition; thus, companies developing treatment options for the same can possess several advantages like 7-year market exclusivity, orphan drug designation, and others.

22q11.2 Deletion Syndrome Market Opportunities
• There exists no approved treatment for the syndrome, as a result, there are several chances for the companies to investigate unmet requirements and develop therapeutic choices that will benefit the patient population and leverage this prevalent orphan indication.

Scope of the 22q11.2 Deletion Syndrome Market Report
• Study Period: 2020-2034
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
• Key 22q11.2 Deletion Syndrome Companies: Zynerba Pharmaceuticals, Inc., Nobias Therapeutics, Inc., Bausch Health Americas, Inc., and others
• Key 22q11.2 Deletion Syndrome Therapies: ZYN002, NB-001, Metyrosine, and others
• 22q11.2 Deletion Syndrome Therapeutic Assessment: 22q11.2 Deletion Syndrome current marketed and 22q11.2 Deletion Syndrome emerging therapies
• 22q11.2 Deletion Syndrome Market Dynamics: 22q11.2 Deletion Syndrome market drivers and 22q11.2 Deletion Syndrome market barriers
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
• 22q11.2 Deletion Syndrome Unmet Needs, KOL's views, Analyst's views, 22q11.2 Deletion Syndrome Market Access and Reimbursement

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: info@delveinsight.com
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting

About DelveInsight
DelveInsight is a leading Healthccare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthccare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

This release was published on openPR.